This website uses cookies to improve your experience.

Cookie policy

Amitriptyline at low-dose and titrated for irritable bowel syndrome as second-line treatment in primary care (ATLANTIS): a randomised, double-blind, placebo-controlled, phase 3 trial.

Ford AC, Wright-Hughes A, Alderson SL, Ow P-L, Ridd MJ, Foy R et al, on behalf of the ATLANTIS Trialists.

Lancet 2023; 402: 1773-1785.

This study included 463 participants, and the outcome was analysed using an IBS symptom scoring system. After six months, patients who received Amitriptyline had significantly lower IBS scores (P=0.0079). Around one fifth of patients in both groups discontinued their medication.

Comment: Useful study with another option for management of this common disease.

Read paper


Part of the charitable activity of the Foundation, BJS Academy is an online educational resource for current and future surgeons.

The Academy is comprised of five distinct sections: Continuing surgical education, Young BJS, Cutting edge, Scientific surgery and Surgical news. Although the majority of this is open access, additional content is available to BJS subscribers and strategic partners.

Discover the Academy
Surgeon Training & Surgeons in Surgery